On 21st, Hanall Biopharma (CEO Kim Seong-uk and CEO Park Seung-guk) has announced that it has achieved the cumulative sales of 60.6 billion KRW, cumulative operating profit of 730 million KRW, and net income of 1 billion KRW till the third quarter.
On this third quarter, Hanall Biopharma has achieved the sales of 20.3 billion KRW, operating profit of 90 million KRW, and net profit of 240 million KRW to accomplish the surplus for three consecutive quarters.
In the third quarter of 2013, Hanall Biopharma has achieved the cumulative sales of 56 billion KRW, operating loss of 7.57 billion KRW, and net loss of 8.79 billion KRW. The Company has increased the sales by 8.1% from the last year, and the operating profit and the net income have turned around into surplus.
One of the staffs has said, “New products launched within 5 years including the anticancer medicine “Eligard” have shown steady growth of sales, and while the annual sales has been decreased for the last three years, it is meaningful that the sales in this year has increased from this year. The Company will successfully achieve the expected performance of 2014 – 82.6 billion KRW of sales, 1 billion KRW of operating profit, and 500 million KRW of net profit – that has been announced in IR of last February.”
NextHanall is Entering into the 60 Billion KRW Market with Peptic Ulcer Drug “Wibis Tab”
PrevHanall Completed the CGMP-class Production Plant for Cutting-edge Solid Formula